© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
January 31, 2017
Dalfampridine extended-release tablets deemed bioequivalent of Amprya.
Dalfampridine extended-release tablets is the bioequivalent of Amprya.
January 28, 2017
The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10 mg).
In a study published in the Journal of Clinical Investigation, the researchers demonstrated a way to promote sensory neuron growth by blocking a specific molecular signaling pathway.